Last updated on July 2019

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma


Brief description of study

This study will evaluate the preliminary efficacy, safety, and pharmacokinetics of cobimetinib and atezolizumab in participants with advanced BRAF V600-wild type (WT), metastatic, or unresectable locally advanced melanoma who have progressed on prior antiPD-1 therapy. In addition, this study will evaluate the efficacy, safety, and pharmacokinetics of atezolizumab monotherapy in participants with BRAFV600-WT metastatic or unresectable locally advanced melanoma, who have not been previously treated.

Clinical Study Identifier: NCT03178851

Find a site near you

Start Over

Angeles Clinic & Rsch Inst

Los Angeles, CA United States
  Connect »

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Blacktown Hospital

Blacktown, Australia
  Connect »

GVI Constantiaberg

Cape Town, South Africa
  Connect »

Johese Clinical Research

Centurion, South Africa
  Connect »

Cancercare

Port Elizabeth, South Africa
  Connect »

Flinders Medical Centre

Bedford Park, Australia
  Connect »

University Clinic Ctr Sarajevo

Sarajevo, Bosnia and Herzegovina
  Connect »

Severance Hospital

Seoul, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Alfred Hospital

Melbourne, Australia
  Connect »

Cancercare

George, South Africa
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.